IL17A and depressive symptom measurement: In psoriasis patients with co-occurring depression, neutralizing antibodies that target Th17 cells (anti-IL-17A, Ixekizumab; anti-IL-12/IL-23, Ustekinumab) have shown promising benefits (96, 97).